about
Novel in vitro and mathematical models for the prediction of chemical toxicityComputational methods in drug discoveryPhysiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.Translating Human Effective Jejunal Intestinal Permeability to Surface-Dependent Intrinsic Permeability: a Pragmatic Method for a More Mechanistic Prediction of Regional Oral Drug Absorption.The promises of quantitative systems pharmacology modelling for drugĀ developmentAddressing human variability in next-generation human health risk assessments of environmental chemicalsNew developments in anti-malarial target candidate and product profilesA Three-Pulse Release Tablet for Amoxicillin: Preparation, Pharmacokinetic Study and Physiologically Based Pharmacokinetic ModelingScreening of chemicals for human bioaccumulative potential with a physiologically based toxicokinetic model.The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data.Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.Physiology-based IVIVE predictions of tramadol from in vitro metabolism data.Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.Interaction Between Domperidone and Ketoconazole: Toward Prediction of Consequent QTc Prolongation Using Purely In Vitro Information.Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development.Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.The simcyp population based simulator: architecture, implementation, and quality assurance.Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development.Influence of mild and moderate hepatic impairment on axitinib pharmacokineticsThe application of global sensitivity analysis in the development of a physiologically based pharmacokinetic model for m-xylene and ethanol co-exposure in humans.A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flowsToxicokinetic Triage for Environmental Chemicals.Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme ActivityAccurate prediction of glucuronidation of structurally diverse phenolics by human UGT1A9 using combined experimental and in silico approaches.Incorporating High-Throughput Exposure Predictions With Dosimetry-Adjusted In Vitro Bioactivity to Inform Chemical Toxicity Testing.A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patients.Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration.Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.In vitro screening for population variability in toxicity of pesticide-containing mixturesAddressing Early Life Sensitivity Using Physiologically Based Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation.Predicted metabolic drug clearance with increasing adult age.Drug delivery trends in clinical trials and translational medicine: evaluation of pharmacokinetic properties in special populationsDose selection based on physiologically based pharmacokinetic (PBPK) approaches.Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients.Population-based mechanistic prediction of oral drug absorption
P2860
Q26851492-E05ADAA8-4026-485B-A4C5-C11393E3FBA1Q26997089-E18EC5FF-178B-4F09-8BB9-221D46DBB3F1Q27312881-3EFE8999-E869-48BE-8AFA-7239E197563AQ27313187-CEA9B080-2101-47E3-8FBB-F30EEFADE809Q28077650-75BE4D30-7522-48B4-90DB-DFD49A6BF2A9Q28393541-B4D3CA48-FA7A-48E1-93CA-E65147D4BCFFQ28468598-DC78353D-150D-48AD-B0AD-18A30DEA0620Q28553344-41A33EF0-80A1-4517-B4A0-8C884A3088B7Q30505431-DD84B983-3BA1-46E5-A7FD-8C638AF2AB7EQ30670381-01038CE8-5EA7-47D1-B492-7B182DDCE5DFQ30688345-2119191D-D209-40EB-B75F-49600D69A1F2Q30837825-17662C1E-BB11-4827-8F6F-80F9DD18043CQ34075909-49F6CBF8-9B29-4064-9ADF-B6AF83150A04Q34099756-77197E1B-B9FF-492A-80B7-8935A4D07871Q34116212-7C97C50A-22FE-486C-BFA5-8EBDC2637CEBQ34143327-DB5D108C-794A-4A4C-B979-CCAF354D2AA0Q34449605-3E2770ED-F236-4BF2-BBE9-1CF53E6D99DAQ34476096-E76B0FBE-942D-4E60-857D-7EA07C11DCEEQ34502721-FF4F5C09-90F5-4D79-9BF1-B2DDEF903130Q35023711-47E1BD3F-50B8-4E5E-A1E8-E3D39EF71E87Q35054518-022C65E0-803E-4790-8A76-E5915D6A843CQ35209594-C6DC2F2B-D4A4-49EA-9509-D6E2F2AC750AQ35796328-F023F986-63E9-48C9-BAE4-8FBDC4BE5BC1Q36025902-86B19A03-8AC7-4429-9FD6-10FDF091FDB3Q36027800-B2733AF8-41E6-4F50-B64A-7ED7C3E3EB2EQ36118294-5F9C8893-E472-4EAF-B723-7A60EE53D41EQ36132276-478AB536-244F-4D30-9C61-2C37268021B9Q36204768-AD4AC74A-4C4D-4771-82EB-EB25867A78D7Q36390289-1B4F75A7-4F5D-482D-82F2-73F24FD2042BQ36506472-34B2B478-004A-4646-A58D-06F94EE6BBF7Q36579268-9839FF0B-71A8-4CDB-A512-09C0CF1ACBFDQ36599597-B8945FA9-0B1C-479C-A724-EC430C93354FQ36636532-6BBF1F6E-C458-48E5-B8F9-97C7C25C7D6AQ36657666-7681D5C9-9E0A-4730-A846-EE1385A60E58Q36729942-FFFAA627-4D67-4CA7-8D9F-ED6BCA93310AQ36901627-1E361A42-DB73-4B61-ADFF-6CF5E58E643BQ36910606-DE572DE5-32FF-44D5-8DF1-279D0D5CD1C5Q36972804-2BE89489-CBD7-4CE8-A5D4-10191AA325C1Q37161962-FC45A9A6-A264-4FB5-8960-CE0D6FB2C55BQ37214520-C0BCAA63-25B9-4A95-8A5B-4FA64AED9DC2
P2860
description
2009 nĆ® lÅ«n-bĆ»n
@nan
2009 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« ÕÕ„ÕæÖÕøÖÕ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2009 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« ÖÕ„ÕæÖÕ¾Õ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2009幓ć®č«ę
@ja
2009幓č«ę
@yue
2009幓č«ę
@zh-hant
2009幓č«ę
@zh-hk
2009幓č«ę
@zh-mo
2009幓č«ę
@zh-tw
2009幓č®ŗę
@wuu
name
The Simcyp population-based ADME simulator
@ast
The Simcyp population-based ADME simulator
@en
The Simcyp population-based ADME simulator
@nl
type
label
The Simcyp population-based ADME simulator
@ast
The Simcyp population-based ADME simulator
@en
The Simcyp population-based ADME simulator
@nl
prefLabel
The Simcyp population-based ADME simulator
@ast
The Simcyp population-based ADME simulator
@en
The Simcyp population-based ADME simulator
@nl
P2093
P2860
P1476
The Simcyp population-based ADME simulator
@en
P2093
Adrian Barnett
Amin Rostami-Hodjegan
Geoffrey Tucker
Kairui Feng
Masoud Jamei
Steve Marciniak
P2860
P304
P356
10.1517/17425250802691074
P407
P577
2009-02-01T00:00:00Z